Meningitis UK Medical PG Practice Questions and MCQs
Practice UK Medical PG questions for Meningitis. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Meningitis UK Medical PG Question 1: A 62-year-old man with diabetes presents with a foot ulcer and fever. X-ray shows bone destruction. Blood cultures grow Staphylococcus aureus. What is the recommended antibiotic duration?
- A. 2 weeks
- B. 4 weeks
- C. 6 weeks
- D. 8-12 weeks (Correct Answer)
- E. 6 months
Meningitis Explanation: ***8-12 weeks***- This prolonged duration is typically recommended for **diabetic foot osteomyelitis (DFO)**, especially when complicated by **Staphylococcus aureus bacteremia** and radiographic evidence of **bone destruction**.- The extended treatment ensures adequate eradication of bacteria from the poorly vascularized bone, which is crucial in diabetic patients prone to **recurrence**.*2 weeks*- This duration is vastly insufficient for established **osteomyelitis**, which requires prolonged therapy due to poor antibiotic penetration into bone and the potential for **biofilm** formation.- A 2-week course is generally reserved for uncomplicated **soft tissue infections** or **cellulitis**, not for deep bone infections with systemic involvement.*4 weeks*- While sometimes used for acute, uncomplicated osteomyelitis without extensive bone involvement, **4 weeks** is typically inadequate for severe cases like **DFO** with **bacteremia** and significant **bone destruction**.- In such complex scenarios, a shorter course significantly increases the risk of **treatment failure** and **relapse**.*6 weeks*- **6 weeks** is considered the standard minimum duration for acute, uncomplicated osteomyelitis, particularly after successful **surgical debridement** of infected bone.- However, for complicated DFO with **S. aureus bacteremia** and significant bone destruction, a longer course, often up to 12 weeks, is frequently necessary, especially if debridement is limited.*6 months*- This exceptionally long duration is generally reserved for very specific, highly refractory infections, such as **tuberculosis osteomyelitis**, or for chronic suppressive therapy in certain **prosthetic joint infections**.- It is typically excessive for **Staphylococcus aureus** DFO when managed with appropriate initial therapy and a standard prolonged course (8-12 weeks).
Meningitis UK Medical PG Question 2: A 22-year-old student presents with fever, headache, and a petechial rash on her legs. CSF shows: protein 2.1 g/L, glucose 1.8 mmol/L (serum 5.2), WCC 850 (90% neutrophils). What is the most likely organism?
- A. Streptococcus pneumoniae
- B. Neisseria meningitidis (Correct Answer)
- C. Haemophilus influenzae
- D. Listeria monocytogenes
- E. Enterovirus
Meningitis Explanation: ***Neisseria meningitidis***- The classic presentation of fever, headache, and a **petechial rash** (indicating **meningococcemia**) in a young adult is highly characteristic of *Neisseria meningitidis* infection.- The CSF profilehigh protein, **low glucose** (low CSF/serum ratio), and **high white cell count** with **predominantly neutrophils** (90%)-is consistent with acute bacterial meningitis caused by this organism.*Streptococcus pneumoniae*- While *Streptococcus pneumoniae* is a common cause of bacterial meningitis with a similar CSF profile (high protein, low glucose, neutrophilic pleocytosis), it is less typically associated with a fulminant **petechial rash**.- This organism often affects extremes of age (very young or elderly) or individuals with specific risk factors such as **pneumonia**, **otitis media**, or **CSF leaks**.*Haemophilus influenzae*- *Haemophilus influenzae* type b (HiB) was a major cause of meningitis in **unvaccinated children** before widespread vaccination, making it less common in immunocompetent young adults.- Although it can cause bacterial meningitis with similar CSF findings, the striking **petechial rash** and patient's age make *Neisseria meningitidis* a more likely diagnosis.*Listeria monocytogenes*- *Listeria monocytogenes* typically causes meningitis in specific vulnerable populations, including **neonates**, the **elderly**, pregnant women, or the **immunosuppressed**.- Given the patient is a healthy 22-year-old student, *Listeria* is a less probable cause compared to *Neisseria meningitidis*.*Enterovirus*- **Enteroviruses** cause **aseptic (viral) meningitis**, which is characterized by a different CSF profile than seen here.- Viral meningitis typically presents with **normal CSF glucose**, normal or mildly elevated protein, and a **lymphocytic pleocytosis** (lymphocyte predominance), which contradicts the 90% neutrophil count in this case.
Meningitis UK Medical PG Question 3: A 37-year-old man presents with acute onset severe headache, fever, and neck stiffness. Lumbar puncture shows lymphocytic pleocytosis with normal glucose. HSV PCR is positive. What is the most appropriate treatment?
- A. IV aciclovir (Correct Answer)
- B. IV ceftriaxone
- C. IV ampicillin
- D. Supportive care only
- E. IV immunoglobulin
Meningitis Explanation: ***IV aciclovir***
- The clinical presentation (acute severe headache, fever, neck stiffness) and cerebrospinal fluid (CSF) findings (**lymphocytic pleocytosis**, **normal glucose**) are highly suggestive of **viral meningoencephalitis**.
- A positive **HSV PCR** in the CSF confirms **Herpes Simplex Virus (HSV) encephalitis**, a severe and potentially fatal condition that necessitates immediate high-dose intravenous **aciclovir**.
*IV ceftriaxone*
- Ceftriaxone is an antibiotic primarily used for **bacterial meningitis**, which typically presents with **neutrophilic pleocytosis** and **low CSF glucose**.
- It is ineffective against **viral infections** like HSV, making it an inappropriate treatment for confirmed HSV encephalitis.
*IV ampicillin*
- Ampicillin is another antibiotic used to treat specific forms of **bacterial meningitis**, particularly covering *Listeria monocytogenes*.
- It does not have antiviral activity and therefore is not an effective treatment for **HSV encephalitis**.
*Supportive care only*
- **HSV encephalitis** carries a high risk of mortality and significant neurological sequelae if left untreated with specific antiviral agents.
- Relying solely on supportive care is insufficient and would be detrimental in a confirmed case of HSV encephalitis.
*IV immunoglobulin*
- Intravenous immunoglobulin (IVIG) is typically used in the management of certain **immunodeficiency syndromes** or **autoimmune disorders**.
- It has no established role or efficacy in the **acute treatment** of viral encephalitis, including that caused by HSV.
Meningitis UK Medical PG Question 4: A 65-year-old man with diabetes presents with a non-healing foot ulcer for 3 months. X-ray shows osteolytic changes in the underlying bone. MRI confirms osteomyelitis. What is the most appropriate treatment duration for antibiotics?
- A. 2 weeks IV
- B. 4 weeks IV
- C. 6 weeks IV
- D. 4-6 weeks IV followed by 2-6 weeks oral
- E. 12 weeks total therapy (Correct Answer)
Meningitis Explanation: ***12 weeks total therapy***- The treatment duration for confirmed **diabetic foot osteomyelitis (DFO)** without amputation or with residual infected bone often requires 10–12 weeks or 3 months of total antibiotic therapy (IV and/or oral) to achieve cure and prevent relapse.- Prolonged treatment is crucial because of the **poor vascular supply** in diabetic feet and the low penetration of antibiotics into the avascular, infected bone.
*2 weeks IV*- This duration is insufficient for bone infection, as antibiotics require extended time to reach therapeutic concentrations within the **avascular, necrotic bone**.- **Acute uncomplicated cellulitis** or soft tissue infection might be treated in 2 weeks, but not osteomyelitis.
*4 weeks IV*- A 4-week course might be considered sufficient only if the infected bone has been completely removed during **surgical debridement** (e.g., partial foot amputation), which is not guaranteed by the prompt.- This duration drastically increases the risk of **relapse** in confirmed, non-surgically cleared osteomyelitis.
*6 weeks IV*- This is the standard duration for **vertebral osteomyelitis** or chronic osteomyelitis where adequate surgical debridement was achieved, often substituting for the total 12-week regimen.- However, for conservative management of **DFO**, guidelines often recommend a total of 10–12 weeks (IV and oral) to maximize bone penetration.
*4-6 weeks IV followed by 2-6 weeks oral*- While this combination (totaling 6–12 weeks) is a common strategy, it is less definitive than the 12-week option and can be interpreted as potentially insufficient depending on the chosen duration (e.g., 6 weeks total is too short).- The **IDSA guidelines** often suggest at least 6 weeks following resection of infected bone, but up to 12 weeks is recommended if bone cannot be fully resected or infection is severe.
Meningitis UK Medical PG Question 5: A 58-year-old woman with diabetes presents with severe foot pain and a deep ulcer exposing bone. X-ray shows osteolytic changes. What is the most likely complication?
- A. Cellulitis
- B. Osteomyelitis (Correct Answer)
- C. Charcot arthropathy
- D. Peripheral arterial disease
- E. Deep vein thrombosis
Meningitis Explanation: ***Osteomyelitis***- The combination of a **deep ulcer exposing bone** and radiologic evidence of **osteolytic changes** strongly indicates infection and destruction of the bone itself.- In patients with **diabetes**, foot ulcers often progress rapidly from soft tissue infection to bone infection due to underlying neuropathy and vascular disease.*Cellulitis*- Cellulitis is a superficial soft tissue infection characterized by erythema, swelling, and warmth, typically without **ulceration exposing bone**.- It affects the dermal and subcutaneous layers and does not cause **osteolytic changes** on X-ray.*Charcot arthropathy*- Charcot foot involves **neuropathic joint destruction** and deformity (e.g., *rocker-bottom* foot), but typically presents with little pain and diffuse bony fragmentation, rather than a localized deep, infected ulcer causing severe pain and lytic changes.- Although common in diabetes, pure Charcot arthropathy is usually sterile; the presence of a deep, draining ulcer points strongly to a progressive infection.*Peripheral arterial disease*- While PAD often contributes to ulcer formation (ischemic ulcers), these ulcers are typically **dry**, **punched-out**, and associated with diminished or absent pedal pulses.- PAD causes ischemia, but the identification of a deep ulcer exposing bone and active **osteolytic changes** points primarily toward a severe, established bone infection.*Deep vein thrombosis*- DVT involves clotting in a deep vein, presenting primarily with **unilateral swelling**, pain, and warmth in the leg (often calf or thigh).- It does not cause localized deep foot ulcers or underlying **osteolytic changes** in the bone.
Meningitis UK Medical PG Question 6: A 19-year-old student presents with fever, headache, and a non-blanching purpuric rash on his legs. Lumbar puncture shows: WCC 2000/μL (95% neutrophils), protein 3.2 g/L, glucose 1.0 mmol/L. Gram stain shows gram-negative diplococci. What is the most appropriate treatment?
- A. IV benzylpenicillin
- B. IV ceftriaxone (Correct Answer)
- C. IV vancomycin
- D. IV ampicillin
- E. Oral ciprofloxacin
Meningitis Explanation: ***IV ceftriaxone***- This third-generation cephalosporin is the **first-line treatment** for suspected bacterial meningitis due to its excellent penetration into the **cerebrospinal fluid (CSF)** and broad coverage of common pathogens like *Neisseria meningitidis*.- The clinical presentation (fever, purpura) and CSF findings (Gram-negative diplococci) confirm **meningococcal meningitis**, necessitating immediate, high-dose parenteral antibiotics.*IV benzylpenicillin*- While IV penicillin is effective against penicillin-sensitive *N. meningitidis*, **penicillin resistance** has been reported, making **ceftriaxone** the preferred initial empirical therapy until antimicrobial susceptibilities are known.- It may be used as targeted monotherapy if the organism is confirmed sensitive, but it is not the universally recommended initial empirical agent for severe disease.*IV vancomycin*- Vancomycin is primarily used to cover **multi-drug resistant *Streptococcus pneumoniae*** or **MRSA**, and is typically unnecessary as monotherapy for a Gram-negative infection like *N. meningitidis*.- Although often included in very broad empirical coverage, it would be insufficient alone and is usually added only if co-infection with resistant Gram-positive organisms is highly suspected.*IV ampicillin*- Ampicillin is primarily added to empirical meningitis regimens to cover **Listeria monocytogenes**, which typically causes disease in neonates, the elderly, or those who are **T-cell immunocompromised**.- It is not indicated as the primary treatment agent for meningococcal disease in an otherwise healthy young adult.*Oral ciprofloxacin*- **Oral ciprofloxacin** is used strictly for **chemoprophylaxis** of close contacts exposed to *N. meningitidis*, such as household members or roommates.- It is ineffective and inappropriate for the treatment of established, life-threatening invasive meningococcal disease, which requires high-dose intravenous therapy.
Meningitis UK Medical PG Question 7: A 35-year-old man with HIV infection (CD4 count 80 cells/mm³, viral load 125,000 copies/mL, not on antiretroviral therapy) presents with a 4-week history of headache, fever, and confusion. CT head shows basal meningeal enhancement and multiple small nodules. Lumbar puncture shows: opening pressure 32 cmH2O, CSF white cells 45/mm³ (80% lymphocytes), protein 1.2 g/L, glucose 1.9 mmol/L (serum glucose 5.4 mmol/L). India ink stain is positive. Cryptococcal antigen is positive in both CSF and serum at titres of 1:2048 and 1:1024 respectively. He is started on liposomal amphotericin B and flucytosine. Which one of the following additional interventions has been shown to improve survival in this patient?
- A. Commencing antiretroviral therapy immediately alongside antifungal treatment
- B. Adding adjunctive dexamethasone 0.4 mg/kg daily for 6 weeks
- C. Performing daily therapeutic lumbar punctures until opening pressure normalizes (Correct Answer)
- D. Adding adjunctive interferon-gamma to enhance immune response
- E. Inserting a ventriculoperitoneal shunt to manage hydrocephalus
Meningitis Explanation: ***Performing daily therapeutic lumbar punctures until opening pressure normalizes***
- Management of **elevated intracranial pressure** (opening pressure >25 cmH2O) is critical, as it is a major cause of mortality in **cryptococcal meningitis** associated with HIV.
- Daily drainage of 20-30 mL of CSF is recommended to achieve an **opening pressure** of <20 cmH2O or a 50% reduction from baseline, which significantly **improves survival** and reduces neurological sequelae.
*Commencing antiretroviral therapy immediately alongside antifungal treatment*
- **Early initiation of ART** (within 2 weeks) in HIV-associated cryptococcal meningitis is associated with an increased risk of **Immune Reconstitution Inflammatory Syndrome (IRIS)** and higher mortality.
- Current guidelines recommend deferring ART for **4 to 6 weeks** after the initiation of induction antifungal therapy to allow for partial clearance of the fungal load and reduce IRIS risk.
*Adding adjunctive dexamethasone 0.4 mg/kg daily for 6 weeks*
- Routine use of **corticosteroids** is contraindicated in cryptococcal meningitis as they have been shown to **increase mortality** and reduce fungal clearance rates in clinical trials.
- Steroids also increase the risk of serious **adverse events** without providing any survival benefit in these patients.
*Adding adjunctive interferon-gamma to enhance immune response*
- While **interferon-gamma** may facilitate faster fungal clearance in some experimental settings, it has not been shown to provide a **survival benefit** in high-quality clinical trials for HIV-associated cryptococcal meningitis.
- It is not currently recommended as part of the **standard induction therapy** for this condition.
*Inserting a ventriculoperitoneal shunt to manage hydrocephalus*
- **Ventriculoperitoneal (VP) shunts** are generally reserved for patients who fail to respond to repeated **therapeutic lumbar punctures** or develop persistent symptomatic hydrocephalus refractory to medical management.
- Although useful for long-term pressure management, it is not the primary or first-line intervention for improving **acute survival** compared to serial lumbar punctures, which are less invasive and carry fewer immediate risks.
Meningitis UK Medical PG Question 8: A 48-year-old woman from Kazakhstan is diagnosed with pulmonary tuberculosis. Initial molecular testing (GeneXpert MTB/RIF) detects Mycobacterium tuberculosis with rifampicin resistance. Subsequent culture and phenotypic drug susceptibility testing confirms resistance to rifampicin and isoniazid, but the isolate is sensitive to pyrazinamide, ethambutol, fluoroquinolones, bedaquiline, and linezolid. She has a history of seizures controlled with carbamazepine and is otherwise well. Which one of the following represents the most significant drug interaction that needs to be considered when designing her MDR-TB treatment regimen?
- A. Linezolid may reduce seizure threshold and interact with carbamazepine
- B. Bedaquiline requires dose adjustment due to carbamazepine-induced enzyme induction
- C. Moxifloxacin may prolong QT interval which is exacerbated by carbamazepine
- D. Carbamazepine induces cytochrome P450 enzymes which will reduce levels of bedaquiline and fluoroquinolones (Correct Answer)
- E. Clofazimine absorption is significantly reduced by carbamazepine
Meningitis Explanation: ***Carbamazepine induces cytochrome P450 enzymes which will reduce levels of bedaquiline and fluoroquinolones***
- **Carbamazepine** is a potent **CYP3A4 inducer**, which significantly increases the metabolism of **Bedaquiline** and certain **fluoroquinolones** (e.g., moxifloxacin), leading to subtherapeutic drug levels.
- This interaction can result in **treatment failure** and the development of further **drug resistance** in patients with **MDR-TB**, making it a critical consideration for regimen design.
*Linezolid may reduce seizure threshold and interact with carbamazepine*
- **Linezolid** is a weak **monoamine oxidase inhibitor (MAOI)**, primarily associated with **serotonin syndrome** in combination with other serotonergic drugs, not a direct significant reduction of the **seizure threshold** or interaction with carbamazepine's antiepileptic effect.
- There is no significant metabolic interaction between Linezolid and **Carbamazepine** that would necessitate avoiding the drug for its impact on seizure control.
*Bedaquiline requires dose adjustment due to carbamazepine-induced enzyme induction*
- While **carbamazepine** does induce **bedaquiline** metabolism, simple **dose adjustment** is often insufficient and not recommended due to the potent and variable nature of enzyme induction.
- Current guidelines typically recommend **avoiding co-administration** of strong CYP3A4 inducers with bedaquiline; if carbamazepine is essential, alternative non-inducing anti-epileptics like **levetiracetam** should be considered.
*Moxifloxacin may prolong QT interval which is exacerbated by carbamazepine*
- Both **Moxifloxacin** and **Bedaquiline** can prolong the **QT interval**, necessitating careful monitoring when used together; however, **Carbamazepine** itself does not significantly exacerbate QTc prolongation.
- The primary concern with **Carbamazepine** in this context is its **enzymatic induction** effect, which reduces the levels of other drugs, rather than an additive electrophysiological effect on cardiac repolarization.
*Clofazimine absorption is significantly reduced by carbamazepine*
- **Clofazimine** absorption is primarily influenced by the presence of food, particularly **fatty meals**, and it is not significantly affected by **cytochrome P450 enzyme induction** by drugs like carbamazepine.
- There is no documented significant pharmacokinetic interaction where **Carbamazepine** reduces **Clofazimine** serum levels to a clinically relevant extent.
Meningitis UK Medical PG Question 9: A 28-year-old previously healthy man is admitted with suspected bacterial meningitis. He is treated empirically with IV ceftriaxone 2 g twice daily and IV dexamethasone 10 mg four times daily. Lumbar puncture performed before antibiotics shows: CSF white cells 2,100/mm³ (90% neutrophils), protein 2.3 g/L, glucose 1.5 mmol/L (serum glucose 6.0 mmol/L). Blood and CSF cultures taken on admission subsequently grow Streptococcus pneumoniae fully sensitive to penicillin (penicillin MIC 0.06 mg/L). He improves clinically over 48 hours. Which one of the following represents the most appropriate modification to his antimicrobial therapy at this stage?
- A. Continue ceftriaxone 2 g twice daily and stop dexamethasone
- B. Switch to benzylpenicillin 2.4 g four-hourly and continue dexamethasone
- C. Switch to amoxicillin 2 g four-hourly and continue dexamethasone
- D. Switch to benzylpenicillin 2.4 g four-hourly and stop dexamethasone (Correct Answer)
- E. Continue ceftriaxone 2 g twice daily and continue dexamethasone for the full 10-day course
Meningitis Explanation: ***Switch to benzylpenicillin 2.4 g four-hourly and stop dexamethasone***
- Once **Streptococcus pneumoniae** is confirmed to be **fully penicillin-sensitive** (MIC ≤ 0.06 mg/L), treatment should be narrowed from ceftriaxone to **high-dose benzylpenicillin** as it is the drug of choice for sensitive strains in meningitis.
- **Dexamethasone** should be stopped because its primary benefit in pneumococcal meningitis is typically achieved within **4 days** of administration, and continuing it beyond this duration, especially with clinical improvement, offers no additional benefit and carries risks of side effects.
*Continue ceftriaxone 2 g twice daily and stop dexamethasone*
- Continuing **ceftriaxone** is unnecessary and represents **overly broad antimicrobial coverage** when a narrow-spectrum, highly effective antibiotic like benzylpenicillin is available for a penicillin-sensitive pathogen.
- While stopping dexamethasone is correct for the reasons mentioned above, failing to **de-escalate** the antibiotic therapy is not in line with good **antimicrobial stewardship** principles.
*Switch to benzylpenicillin 2.4 g four-hourly and continue dexamethasone*
- Although switching to **benzylpenicillin** is the correct choice for a penicillin-sensitive *Streptococcus pneumoniae* infection, continuing **dexamethasone** indefinitely or beyond the recommended duration (typically **4 days**) is not indicated.
- The adjunctive benefit of dexamethasone is primarily during the initial inflammatory phase, and its continued use after clinical improvement and pathogen identification is generally not supported by evidence for routine cases.
*Switch to amoxicillin 2 g four-hourly and continue dexamethasone*
- **Intravenous benzylpenicillin (penicillin G)** is preferred over amoxicillin for treating bacterial meningitis due to its superior and more consistent **cerebrospinal fluid (CSF) penetration** at high doses, which is crucial for CNS infections.
- Continuing **dexamethasone** in a patient improving clinically with a penicillin-sensitive organism is not appropriate; its use is typically limited to the initial 4-day course.
*Continue ceftriaxone 2 g twice daily and continue dexamethasone for the full 10-day course*
- Maintaining **broad-spectrum ceftriaxone** when the pathogen's **MIC confirms penicillin sensitivity** is inappropriate, contributing to the risk of **antibiotic resistance** and potential drug-related adverse effects.
- A **10-day course of dexamethasone** for pneumococcal meningitis is not supported by current clinical guidelines, which recommend a maximum of **4 days** of adjunctive steroid therapy.
Meningitis UK Medical PG Question 10: A 56-year-old man with end-stage renal failure on haemodialysis three times per week is diagnosed with fully drug-sensitive pulmonary tuberculosis. He weighs 70 kg. His renal function shows: creatinine 680 micromol/L, eGFR <10 mL/min/1.73m². Which one of the following represents the most appropriate dosing regimen for the intensive phase of treatment?
- A. Rifampicin 600 mg once daily, isoniazid 300 mg once daily, pyrazinamide 1.5 g three times per week post-dialysis, ethambutol 600 mg three times per week post-dialysis (Correct Answer)
- B. Rifampicin 450 mg once daily, isoniazid 200 mg once daily, pyrazinamide 1 g once daily, ethambutol 800 mg three times per week post-dialysis
- C. Rifampicin 600 mg three times per week post-dialysis, isoniazid 300 mg three times per week post-dialysis, pyrazinamide 25 mg/kg three times per week post-dialysis, ethambutol 15 mg/kg three times per week post-dialysis
- D. Rifampicin 600 mg once daily, isoniazid 300 mg three times per week post-dialysis, pyrazinamide 25 mg/kg three times per week post-dialysis, ethambutol 15 mg/kg three times per week post-dialysis
- E. Rifampicin 600 mg once daily, isoniazid 300 mg once daily, pyrazinamide 500 mg once daily, ethambutol 400 mg once daily
Meningitis Explanation: ***Rifampicin 600 mg once daily, isoniazid 300 mg once daily, pyrazinamide 1.5 g three times per week post-dialysis, ethambutol 600 mg three times per week post-dialysis***- **Rifampicin** and **isoniazid** are primarily metabolized by the **liver**, so standard daily doses are maintained regardless of renal function or dialysis.- **Pyrazinamide** and **ethambutol** (or their metabolites) are **renally excreted** and cleared by dialysis; they must be given **thrice weekly after dialysis** to prevent toxic accumulation while maintaining efficacy.*Rifampicin 450 mg once daily, isoniazid 200 mg once daily, pyrazinamide 1 g once daily, ethambutol 800 mg three times per week post-dialysis*- The **rifampicin** and **isoniazid** doses are inappropriately low for a 70 kg patient, as their metabolism is independent of renal clearance.- Daily dosing of **pyrazinamide** is contraindicated in **ESRF** due to the high risk of **hyperuricemia** and **hepatotoxicity** from metabolite buildup.*Rifampicin 600 mg three times per week post-dialysis, isoniazid 300 mg three times per week post-dialysis, pyrazinamide 25 mg/kg three times per week post-dialysis, ethambutol 15 mg/kg three times per week post-dialysis*- **Rifampicin** and **isoniazid** should not be switched to intermittent dosing solely based on renal failure, as they require daily administration for optimal plasma levels and efficacy.- Reducing the frequency of these particular drugs increases the risk of **treatment failure** and the development of **drug resistance**.*Rifampicin 600 mg once daily, isoniazid 300 mg three times per week post-dialysis, pyrazinamide 25 mg/kg three times per week post-dialysis, ethambutol 15 mg/kg three times per week post-dialysis*- While the pyrazinamide and ethambutol adjustments are correct, **isoniazid** does not require a reduction in frequency for dialysis patients.- Standard **isoniazid** 300 mg daily dosing ensures adequate exposure, especially in **fast acetylators**, even with low **eGFR**.*Rifampicin 600 mg once daily, isoniazid 300 mg once daily, pyrazinamide 500 mg once daily, ethambutol 400 mg once daily*- Administering **ethambutol** daily in renal failure, even at low doses, significantly increases the risk of **optic neuritis** due to cumulative toxicity.- Daily dosing of **pyrazinamide** in ESRF leads to the accumulation of several toxic metabolites which cannot be managed safely by simple dose reduction; intermittent dosing is the standard of care.
More Meningitis UK Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
